PainChek Ltd (PCK) AI Stock Analysis

PainChek is a digital health company focused on AI-assisted pain assessment and monitoring for patients who cannot reliably self-report pain. Its software combines facial analysis with clinical assessment tools, numerical pain scoring, reporting and...

In FY2026, PainChek’s implemented licences increased 27.9% to 90,198, while implemented annual recurring revenue rose 24.6% to $4.46 million. Recognised customer revenue reached $3.74 million, customer cash receipts rose 13.6% to $4 million, an...

PainChek is a healthcare technology company focused on digital pain assessment and monitoring for people who cannot reliably self-report pain. Its application combines AI-assisted facial analysis with structured clinical assessments and reporting too...

PainChek Limited has announced the cessation of John Murray as a director effective 26 October 2026, documenting his final interests in the company’s securities in accordance with ASX disclosure requirements. The notice details Murray’s d...

PainChek reported solid growth for the September 2026 quarter, with unaudited customer revenue rising 12.9% from the previous quarter to $1.210 million and 42.4% year on year, while customer retention improved to 90% and activated licences reached 91...

PainChek has announced the retirement of non-executive director and former chair John Murray, who leaves the board after a decade in which he oversaw the company’s evolution from an early-stage technology developer to a commercial business with...

PainChek Ltd has notified the market of the issue of 2,200,000 unquoted performance rights under its employee incentive scheme, recorded as Appendix 3G with the ASX. The new securities, designated as PCKAA performance rights and issued on 8 October 2...

PainChek has expanded its commercial footprint in the U.S. through Sabra Health Care REIT, growing from two initial Traditions memory care facilities to 23 communities across five national operators, with 808 contracted memory care licences. The roll...

PainChek Limited has reported a change in director Adam Davey’s interests following the conversion of 48,426 performance rights into fully paid ordinary shares. As a result, Davey’s direct holding increased to 105,084 shares, while his in...

PainChek Ltd has applied for quotation of 242,130 new ordinary fully paid shares on the Australian Securities Exchange, under the ticker PCK, following the exercise or conversion of existing options or other convertible securities. The modest issuanc...

PainChek Ltd has scheduled its Annual General Meeting for shareholders at 3 p.m. AEDT on Wednesday, 4 November 2026, to be held at its Sydney offices. The notice outlines the formal business of the meeting, including resolutions and explanatory mater...

PainChek has released its 2026 Corporate Governance Statement, outlining how its board oversees management and aligns with the ASX Corporate Governance Council’s latest principles and recommendations. The document details formal structures such...

PainChek signalled that the 2026 financial year marks the start of its next growth phase, leveraging an established customer base and rising recurring revenue. The company highlighted that securing regulatory access in the U.S. and other regions is o...

PainChek Limited has disclosed a final director’s interest notice following the resignation of director Ross Harricks on 1 September 2026. The filing outlines Harricks’ remaining holdings in the company, including fully paid ordinary shar...

PainChek Ltd, a healthcare technology company specialising in AI-driven pain assessment tools, is expanding its presence across key international healthcare markets following regulatory clearances in regions including Australia, Europe, and the Unite...

PainChek Ltd reported total revenue of $4.9 million for the year ended 30 June 2026, a modest increase of 2% on the prior year, supported by higher core revenue and interest income but offset by a reduction in grants. The company’s net loss att...

PainChek Ltd, a medical device and AI-enabled pain assessment specialist, is expanding its global footprint with regulatory clearances across multiple regions including recent FDA De Novo clearance in the United States, and has built a substantial pr...

PainChek Ltd has updated its previously reported figures for unquoted performance rights following a recent share consolidation, revising the allocations for several key individuals, including J. Murray, R. Harricks, C. Payne and A. Davey. The total...